<C10647191 1/08/06

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/CAplus - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 14 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16 DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 17 DEC 16 MARPATprev will be removed from STN on December 31, 2005
NEWS 18 DEC 21 IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 19 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS DCOST SINCE APPROXIMATELY 20:00 COLUMBUS TIME DECEMBER 29,
SOME ONLINE COST DISPLAYS HAVE BEEN SHOWING COSTS IN
2006 PRICES FOR STN COLUMBUS FILES. THIS HAS BEEN
CORRECTED. PLEASE BE ASSURED THAT YOU WILL BE BILLED
ACCORDING TO 2005 PRICES UNTIL JAN 1. PLEASE CONTACT
YOUR LOCAL HELP DESK IF YOU HAVE ANY QUESTIONS. WE
APOLOGIZE FOR THE ERROR.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN

<C10647191 1/08/06

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:20:30 ON 09 JAN 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:20:41 ON 09 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JAN 2006 HIGHEST RN 871465-69-9
DICTIONARY FILE UPDATES: 8 JAN 2006 HIGHEST RN 871465-69-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10647191.str





chain nodes :
6 7 8 9 10
ring nodes :
1 2 3 4 5
chain bonds :
2-6 5-7 7-8 8-9 9-10
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 2-6 3-4 4-5 7-8 8-9 9-10
exact bonds :
5-7
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 07:21:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13407 TO ITERATE

14.9% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

<C10647191 1/08/06

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 261204 TO 275076
PROJECTED ANSWERS: 1 TO 289

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:21:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 269257 TO ITERATE

100.0% PROCESSED 269257 ITERATIONS 258 ANSWERS
SEARCH TIME: 00.00.12

L3 258 SEA SSS FUL L1

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 170.46 170.67

FILE 'REGISTRY' ENTERED AT 07:25:48 ON 09 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JAN 2006 HIGHEST RN 871465-69-9
DICTIONARY FILE UPDATES: 8 JAN 2006 HIGHEST RN 871465-69-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\106471911.str



chain nodes :
6 7 8 9 10 16 17
ring nodes :
1 2 3 4 5
chain bonds :
2-6 5-7 7-8 8-9 8-16 9-10 16-17
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 2-6 3-4 7-8 8-9 8-16 9-10 16-17
exact bonds :
4-5 5-7
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
16:CLASS 17:Atom

L4 STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 07:26:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13407 TO ITERATE

14.9% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 261204 TO 275076
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=>
Uploading C:\Program Files\Stnexp\Queries\106471912.str



chain nodes :
6 7 8 9 10 16 17
ring nodes :
1 2 3 4 5
chain bonds :
2-6 5-7 7-8 8-9 8-16 9-10 16-17
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 2-6 3-4 4-5 7-8 8-9 8-16 9-10 16-17
exact bonds :
5-7
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
16:CLASS 17:Atom

L6 STRUCTURE UPLOADED

=> d
L6 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l6
SAMPLE SEARCH INITIATED 07:27:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13407 TO ITERATE

14.9% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 261204 TO 275076
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s l6 full
FULL SEARCH INITIATED 07:27:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 269257 TO ITERATE

100.0% PROCESSED 269257 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.12

L8 16 SEA SSS FUL L6

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 167.82 338.49

FILE 'CAPLUS' ENTERED AT 07:27:50 ON 09 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

<C10647191 1/08/06

strictly prohibited.

FILE COVERS 1907 - 9 Jan 2006 VOL 144 ISS 3
FILE LAST UPDATED: 8 Jan 2006 (20060108/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l8
L9 6 L8

=> d ibib abs hitstr tot

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:902086 CAPLUS
DOCUMENT NUMBER: 141:388753
TITLE: Heterocyclic compound modulators of Tie-2 and other kinases, and therapeutic use
INVENTOR(S): Chen, Jeff; Dalrymple, Lisa; Epshteyn, Sergery; Forsyth, Timothy; Huynh, Tai; Leahy, James; Mann, Grace; Mann, Larry W.; Ridgway, Brian; Sangalang, Joan C.; Takeuchi, Craig
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091480	A2	20041028	WO 2004-US10626	20040408
WO 2004091480	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2520255	AA	20041028	CA 2004-2520255	20040408
EP 1611123	A2	20060104	EP 2004-759191	20040408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-461471P P 20030409
WO 2004-US10626 W 20040408
OTHER SOURCE(S): MARPAT 141:388753
AB The invention provides heterocyclic compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compds. and pharmaceutical compns. thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention. Preparation of triazolyl compds. of the invention is included.
IT 783327-03-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic compound modulators of Tie-2 and other kinases, and therapeutic use)
RN 783327-03-7 CAPLUS
CN 1-Naphthaleneacetamide, N-cyclopentyl-N-[2-[5-(4-methoxyphenyl)-2-(4-pyridinyl)-1H-imidazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:327187 CAPLUS
DOCUMENT NUMBER: 140:321364
TITLE: Preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators
INVENTOR(S): Thurkauf, Andrew; He, Xiao-shu; Zhao, He; Peterson, John; Zhang, Xiaoyan; Brodbeck, Robbin; Krause, James; Maynard, George; Hutchison, Alan
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: U.S., 592 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6723743	B1	20040420	US 2000-672071	20000928
US 6884815	B1	20050426	US 2003-461311	20030612

PRIORITY APPLN. INFO.: US 1999-156390P P 19990928
US 2000-202749P P 20000508
US 2000-212499P P 20000616
US 2000-221787P P 20000731
US 2000-224036P P 20000809
US 2000-212449P P 20000616
US 2000-672071 A3 20000928
OTHER SOURCE(S): MARPAT 140:321364
GI



AB The invention includes low mol. weight, non-peptidic, non-peptidommetic, organic mols. that can act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also such ligands that can act as antagonists or inverse agonists of complement C5a receptors. Preferred compds. of the invention possess some or all of the following properties in that they are: (1) multi-aryl in structure; (2) heteroaryl in structure; (3) a pharmaceutically acceptable oral dose can provide a detectable in vivo effect; (4) comprise fewer than four or preferably no amide bonds, and (5) capable of habiting leukocyte chemotaxis at nanomolar or sub-nanomolar concns. Such compds. include mainly substituted arylimidazoles I (m = 0-2; R1 = H, OH, halo, NH2, etc.; R2 = alkyl, cycloalkyl, haloalkyl, etc.; R31, R32, R5, R6 = H, OH, halo,

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NH2, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; R7 = 0-3 groups selected from halo, NO2, CN, CF3, etc.], and also pyrazoles, amides, etc. Detailed prepn. of some of the title compds. was given. E.g., a multi-step synthesis of I [Ar1 = Ph; R1, R31, R32, R7 = H; R2 = Bu; R4 = 3,4-methylenedioxyphenyl] was presented. The invention also includes pharmaceutical compn. comprising the title compds. and the use of such compds. in treating a variety disorders.
IT 439558-54-0P 439558-56-2P 439558-58-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators)
RN 439558-54-0 CAPLUS
CN 1H-Imidazole-5-methanamine, N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 439558-56-2 CAPLUS
CN 1H-Imidazole-5-methanamine, N-(1,3-benzodioxol-5-ylmethyl)-1-butyl-N-(phenylmethyl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 439558-58-4 CAPLUS
CN 1H-Imidazole-5-methanamine, N-(1,3-benzodioxol-5-ylmethyl)-1-butyl-N-(cyclopentylmethyl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:182872 CAPLUS
DOCUMENT NUMBER: 140:235712
TITLE: Preparation of aminomethyl imidazoles as complement C5a receptor modulators
INVENTOR(S): Thurkauf, Andrew; Zhao, He; Zhang, Suoming; Gao, Yang
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018460	A1	20040304	WO 2003-US26432	20030821
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004082577	A1	20040429	US 2003-647191	20030821
PRIORITY APPLN. INFO.:			US 2002-405186P P	20020821
OTHER SOURCE(S):	MARPAT 140:235712			

GI



AB Aminomethyl imidazoles of formula I [R = H, halo, CN, alkyl, etc.; R1 = H, OH, halo, amino, CN, nitro, alkyl, etc.; R2 = alkyl, alkenyl; R3 = H, alkyl; R4 = alkyl, arylalkyl, etc.; R5, R6 = H, alkyl; Ar = aryl, heteroaryl, fused Ph, etc.] are prepared which are ligands of C5a receptors. Preferred compds. bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The compds. can be used for the treatment of a variety of inflammatory,

L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
cardiovascular, and immune system disorders. Pharmaceutical compns. contg. compds. of formula I are described. Addnl., this invention provides labeled aminomethyl imidazoles compds., which are useful as probes for the localization of C5a receptors. Thus, II was prepd. from morpholine, bromodichlorobutylimidazole and (dihydrobenzodioxinylmethyl)(ethoxybenzyl)amine. Many of the prepd. compds. exhibit a Ki value of less than 1 μM in an assay of C5a receptor mediated calcium mobilization.

IT **666834-05-5P 666834-06-6P 666834-15-7P 666834-16-8P 666834-22-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminomethyl imidazoles as complement C5a receptor modulators)

RN 666834-05-5 CAPLUS
CN 1H-Imidazole-5-methanamine, 1-butyl-4-chloro-N-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-N-[(3-ethoxyphenyl)methyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 666834-06-6 CAPLUS
CN 1H-Imidazole-5-methanamine, 1-butyl-4-chloro-N-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-N-[(3-ethoxyphenyl)methyl]-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 666834-15-7 CAPLUS
CN Benzoic acid, 4-[[[[1-butyl-4-chloro-2-(4-morpholinyl)-1H-imidazol-5-yl]methyl][(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 666834-16-8 CAPLUS
CN Benzoic acid, 4-[[[[1-butyl-4-chloro-2-(4-morpholinyl)-1H-imidazol-5-yl]methyl][(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 666834-22-6 CAPLUS
CN 1H-Imidazole-5-methanamine, 1-butyl-4-chloro-N-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-N-[(3-ethoxyphenyl)methyl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(phenylmethyl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:818275 CAPLUS
DOCUMENT NUMBER: 139:286343
TITLE: Combination therapy using a C5a antagonist and a C5a receptor-inactive therapeutic agent for the treatment of conditions with pathogenic inflammatory components
INVENTOR(S): Krause, James
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 221 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084524	A1	20031016	WO 2003-US9424	20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480082	AA	20031016	CA 2003-2480082	20030327
US 2004014782	A1	20040122	US 2003-401113	20030327
EP 1490044	A1	20041229	EP 2003-716867	20030327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005530719	T2	20051013	JP 2003-581764	20030327

PRIORITY APPLN. INFO.: US 2002-368925P P 20020329
WO 2003-US9424 W 20030327

OTHER SOURCE(S): MARPAT 139:286343

AB Compns. and methods for treating diseases that are associated with inflammation are provided. Such diseases include arthritis (particularly rheumatoid arthritis) and other autoimmune disorders, asthma, cardio-and cerebrovascular disease, burns, psoriasis, reperfusion injury, and traumatic CNS and spinal cord injury. The compns. generally comprise at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent. The methods involve co-administration of at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent to a patient. The C5a antagonist and C5a receptor-inactive therapeutic agent may be present within the same composition, or may be administered sep. to the patient.

IT **439558-56-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C5a antagonist-C5a receptor-inactive therapeutic agent combination for treatment of condition with pathogenic inflammatory component)

RN 439558-56-2 CAPLUS
CN 1H-Imidazole-5-methanamine, N-(1,3-benzodioxol-5-ylmethyl)-1-butyl-N-

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:796668 CAPLUS
DOCUMENT NUMBER: 139:307760
TITLE: Preparation of new aryl imidazoles and related compounds as C5a receptor modulators
INVENTOR(S): Luke, George P.; Maynard, George; Mitchell, Scott; Thurkauf, Andrew; Xie, Linghong; Zhang, Luyan; Zhang, Suoming; Zhao, He; Chenard, Bertrand L.; Gao, Yang; Han, Bingsong; He, Xiao Shu
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 356 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082829	A1	20031009	WO 2003-US9938	20030328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480888	AA	20031009	CA 2003-2480888	20030328
US 2004116424	A1	20040617	US 2003-405989	20030328
EP 1490343	A1	20041229	EP 2003-726169	20030328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005528368	T2	20050922	JP 2003-580297	20030328

PRIORITY APPLN. INFO.: US 2002-369112P P 20020329
US 2002-392145P P 20020626
WO 2003-US9938 W 20030328

OTHER SOURCE(S): MARPAT 139:307760
GI

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II

AB The title imidazoles, pyrazoles, pyridizines [I; the ring system in the formula I = 5-membered heteroaryl ring system (in which x = 0, A = C, N, O, S, and E and G = C, N, provided that the 5-membered heteroaryl ring system does not contain more than 3 heteroatoms or more than 1 O or S atom) or 6-membered heteroaryl ring system (in which x = 1, A, B, E, and G = C, N, and provided that the 6-membered heteroaryl ring system does not contain more than 3 N atoms); R, R1 = H, OH, halo, etc.; when E = N, then R2 = alkyl, alkenyl, CH2Ph, etc.; when E = C, then R2 = H, halo, OH, etc.; R3 = H, alkyl, alkenyl, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; R5, R6 = H, alkyl; z = 1-3; Ar1 = (un)substituted aryl, heteroaryl, Ph fused to 5-7 membered (un)saturated ring that has 0-2 ring atoms chosen from N, O, and S; Ar2 = cycloalkyl, cycloalkylalkyl, aryl having 1 ring or 2 fused or pendant rings, etc.; y = 1-6] which are ligands of C5a receptors, were prepared and formulated. E.g., a multi-step synthesis of II (starting from Me benzimidate hydrochloride and 1-butylamine), was given. Preferred compds. I bind to C5a receptors with high affinity (biol. data given) and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compns. comprising such compds. It further relates to the use of such compds. in treating a variety of inflammatory and immune system disorders.

IT **610287-35-9P 610287-86-0P 610288-15-8P**
610294-29-6P 610295-02-8P 610295-41-5P
610298-53-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of new aryl imidazoles and related compds. as C5a receptor modulators)

RN 610287-35-9 CAPLUS
CN 1H-Imidazole-5-methanamine, N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-4-phenyl-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 610287-86-0 CAPLUS
CN 1H-Imidazole-5-methanamine, 1-butyl-N-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-N-[(3-ethoxyphenyl)methyl]-4-phenyl-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 610288-15-8 CAPLUS
CN 1H-Imidazole-5-methanamine, N-(1,3-benzodioxol-5-ylmethyl)-1-butyl-N-[(3-ethoxyphenyl)methyl]-4-phenyl-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 610294-29-6 CAPLUS
CN 1H-Imidazole-5-methanamine, 2-(1,3-benzodioxol-5-yl)-N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-4-phenyl- (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 610295-02-8 CAPLUS
CN 1H-Imidazole-5-methanamine, N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 610295-41-5 CAPLUS
CN 1H-Imidazole-5-methanamine, 1-butyl-N-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-N-[(3-ethoxyphenyl)methyl]-2-(2-methyl-4-thiazolyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 610298-53-8 CAPLUS
CN Benzamide, 4-[[[[1-butyl-4-(4-methoxyphenyl)-2-(4-pyridinyl)-1H-imidazol-5-yl]methyl](cyclohexylmethyl)amino]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:487497 CAPLUS
DOCUMENT NUMBER: 137:78952
TITLE: Preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators
INVENTOR(S): Thurkauf, Andrew; Zhang, Xiaoyan; He, Xia-Shu; Zhao, He; Peterson, John; Maynard, George; Ohliger, Robert
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 609 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049993	A2	20020627	WO 2000-US26816	20000929
WO 2002049993	A3	20030220		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2420215	AA	20020627	CA 2000-2420215	20000929
AU 2000076225	A5	20020701	AU 2000-76225	20000929
EP 1322309	A2	20030702	EP 2000-965522	20000929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
ZA 2003001160	A	20040212	ZA 2003-1160	20000929
BR 2000017338	A	20040427	BR 2000-17338	20000929
JP 2004525873	T2	20040826	JP 2002-551496	20000929
NO 2003001370	A	20030530	NO 2003-1370	20030326
PRIORITY APPLN. INFO.:			US 2000-227454P P	20000823
			WO 2000-US26816 W	20000929

OTHER SOURCE(S): MARPAT 137:78952
GI


I


II

AB The invention includes low mol. weight, non-peptidic, non-peptidommetic, organic
mols. that can act as modulators of mammalian complement C5a receptors,

L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 439558-58-4 CAPLUS
CN 1H-Imidazole-5-methanamine, N-(1,3-benzodioxol-5-ylmethyl)-1-butyl-N-(cyclopentylmethyl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
preferably ones that act as high affinity C5a receptor ligands and also such ligands that can act as antagonists or inverse agonists of complement C5a receptors. Preferred compds. of the invention possess some or all of the following properties in that they are: (1) multi-aryl in structure; (2) heteroaryl in structure; (3) a pharmaceutically acceptable oral dose can provide a detectable in vivo effect; (4) comprise fewer than four or preferably no amide bonds, and (5) capable of habiting leukocyte chemotaxis at nanomolar or sub-nanomolar concns. Such compds. include imidazoles I [R1 = H, OH, halo, etc.; R2 = alkyl, cycloalkyl, etc.; R3 H, alkyl, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; Ar1, Ar2 = (un)substituted carbocyclic aryl, arylalkyl, etc.], pyrazoles II [R = H, OH, halo, etc.; R2, R3 = H, OH, halo, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; Ar1, Ar2 = (un)substituted carbocyclic aryl, arylalkyl, etc.], amides Ar1CONR1R2 [III; R1, R2 = alkyl, alkenyl, cycloalkyl, etc.; Ar1 = (un)substituted carbocyclic aryl, arylalkyl, etc.], etc. Detailed prepn. of some compds. I-III was given. E.g., a multi-step synthesis of I [Ar1 = Ph; R1, R3 = H; R2 = Bu; R4, Ar2 = 3,4-methylenedioxyphenyl] was presented. The invention also includes pharmaceutical compn. comprising such compds. I-III and the use of such compds. in treating a variety of inflammatory and immune system disorders.

IT **439558-54-0P 439558-56-2P 439558-58-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators)

RN 439558-54-0 CAPLUS
CN 1H-Imidazole-5-methanamine, N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 439558-56-2 CAPLUS
CN 1H-Imidazole-5-methanamine, N-(1,3-benzodioxol-5-ylmethyl)-1-butyl-N-(phenylmethyl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)

<C10647191 1/08/06

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.12	369.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.50	-4.50

STN INTERNATIONAL LOGOFF AT 07:28:30 ON 09 JAN 2006